Brokerages Expect Kindred Biosciences Inc (KIN) Will Post Earnings of -$0.40 Per Share

Equities analysts expect Kindred Biosciences Inc (NASDAQ:KIN) to announce ($0.40) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Kindred Biosciences’ earnings. The lowest EPS estimate is ($0.42) and the highest is ($0.38). Kindred Biosciences posted earnings per share of ($0.29) during the same quarter last year, which suggests a negative year over year growth rate of 37.9%. The company is scheduled to issue its next earnings results on Tuesday, November 6th.

On average, analysts expect that Kindred Biosciences will report full-year earnings of ($1.51) per share for the current fiscal year, with EPS estimates ranging from ($1.56) to ($1.44). For the next year, analysts anticipate that the firm will post earnings of ($1.22) per share, with EPS estimates ranging from ($1.37) to ($1.04). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Kindred Biosciences.

Kindred Biosciences (NASDAQ:KIN) last announced its quarterly earnings data on Thursday, August 9th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.38) by ($0.01).

Several analysts have issued reports on KIN shares. EuroPacific Canada started coverage on shares of Kindred Biosciences in a research note on Wednesday, May 23rd. They issued a “buy” rating and a $16.75 price objective for the company. Zacks Investment Research downgraded shares of Kindred Biosciences from a “buy” rating to a “hold” rating in a research note on Wednesday, August 15th. BidaskClub downgraded shares of Kindred Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, June 20th. ValuEngine downgraded shares of Kindred Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Thursday, June 28th. Finally, Cantor Fitzgerald set a $20.00 price objective on shares of Kindred Biosciences and gave the stock a “buy” rating in a research note on Wednesday. Three investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. Kindred Biosciences presently has a consensus rating of “Buy” and a consensus price target of $16.75.

Shares of NASDAQ KIN opened at $13.75 on Tuesday. Kindred Biosciences has a 1 year low of $6.80 and a 1 year high of $15.75.

In related news, major shareholder Park West Asset Management Llc purchased 845,262 shares of the firm’s stock in a transaction dated Wednesday, June 20th. The stock was purchased at an average price of $9.50 per share, with a total value of $8,029,989.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Richard Chin sold 40,000 shares of Kindred Biosciences stock in a transaction that occurred on Monday, July 2nd. The shares were sold at an average price of $10.28, for a total transaction of $411,200.00. Following the sale, the insider now directly owns 2,146,071 shares of the company’s stock, valued at approximately $22,061,609.88. The disclosure for this sale can be found here. Insiders have sold 120,000 shares of company stock valued at $1,543,200 in the last ninety days. Insiders own 15.96% of the company’s stock.

Institutional investors have recently bought and sold shares of the company. Ariel Investments LLC raised its stake in Kindred Biosciences by 25.9% in the second quarter. Ariel Investments LLC now owns 2,218,612 shares of the biopharmaceutical company’s stock worth $23,628,000 after buying an additional 456,783 shares in the last quarter. Renaissance Technologies LLC raised its stake in Kindred Biosciences by 36.5% in the second quarter. Renaissance Technologies LLC now owns 948,700 shares of the biopharmaceutical company’s stock worth $10,104,000 after buying an additional 253,500 shares in the last quarter. BlackRock Inc. raised its stake in Kindred Biosciences by 20.1% in the second quarter. BlackRock Inc. now owns 1,325,147 shares of the biopharmaceutical company’s stock worth $14,114,000 after buying an additional 221,578 shares in the last quarter. Granahan Investment Management Inc. MA raised its stake in Kindred Biosciences by 92.9% in the second quarter. Granahan Investment Management Inc. MA now owns 318,741 shares of the biopharmaceutical company’s stock worth $3,395,000 after buying an additional 153,479 shares in the last quarter. Finally, Sit Investment Associates Inc. bought a new position in Kindred Biosciences in the second quarter worth approximately $752,000. 62.59% of the stock is owned by hedge funds and other institutional investors.

Kindred Biosciences Company Profile

Kindred Biosciences, Inc, a biopharmaceutical company, focuses on the development of therapies for pets. The company's product pipeline includes small molecules and biologics for a range of indications in dogs, cats, and horses. Its lead product candidates comprise Zimeta, a dipyrone injection for the control of pyrexia (fever) in horses; and Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats.

See Also: Asset Allocation and Your Retirement

Get a free copy of the Zacks research report on Kindred Biosciences (KIN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kindred Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply